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Abstract
Inflammatory bowel diseases (IBD) comprise the two 
major entities Crohn’s disease and ulcerative colitis 
and endoscopic imaging of the gastrointestinal tract 
has always been an integral and central part in the 
management of IBD patients. Within the recent years, 
mucosal healing emerged as a key treatment goal 
in IBD that substantially decides about the clinical 
outcome of IBD patients, thereby demanding for a 
precise, timely and detailed endoscopic assessment of 
the mucosal inflammation associated with IBD. Further, 
molecular imaging has tremendously expanded the 
clinical utility and applications of modern endoscopy, 
now encompassing not only diagnosis, surveillance, 
and treatment but also the prediction of individual 
therapy response. Within this review we describe novel 
endoscopic approaches and advanced endoscopic 
imaging methods for the diagnosis, treatment and 
surveillance of IBD patients. We begin by providing an 
overview over novel and advanced imaging techniques 
such as magnification endoscopy and dye-based and 
dye-less chromoendoscopy, endomicroscopy and 
endocytoscopy. We then describe how these techniques 
can be utilized for the precise and ultrastructural 
assessment of mucosal inflammation and dysplasia 
development associated with IBD and outline how 
they have enabled the endoscopist to gain insight onto 
the cellular level in real-time. Finally, we provide an 
outlook on how molecular imaging has rapidly evolved 
in the recent past and can be used to make individual 
predictions about the therapeutic response towards 
biological treatment. 
Key words: Gastrointestinal endoscopy; Crohn’s disease; 
Ulcerative colitis; Inflammatory bowel diseases; Colon; 
Colorectal neoplasms
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Within this review we describe novel endo-
scopic techniques for the diagnosis, treatment and 
surveillance of inflammatory bowel diseases (IBD) 
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patients. We begin by providing an overview over 
advanced imaging techniques such as magnification 
endoscopy, dye-based and dye-less chromoendoscopy, 
endomicroscopy and endocytoscopy. We then portray 
how these techniques provide insights on cellular level 
in real-time and how they can be utilized for the precise 
and ultrastructural assessment of mucosal inflammation 
and dysplasia development in IBD. Finally, we review 
how molecular imaging has rapidly evolved in the 
recent past and can now be used to make individual 
predictions about the therapeutic response towards 
biological treatment.
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INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) 
belong to the family of idiopathic inflammatory bowel 
diseases (IBD) in which an excessive mucosal immune 
response towards the complex enteric microbiota in a 
genetically predisposed host is believed to play a key 
role in disease pathophysiology[1-4]. It is well accepted 
that the chronic inflammatory stimulus within the 
gastrointestinal tract is associated with an increased 
risk for developing colitis associated cancer (CAC) in 
both, UC and CD[5] and the individual risk for colon 
cancer increases with the duration, severity and 
anatomic extent of colitis[6-10]. The close association 
between disease duration and the development of CAC 
represents the rationale for recommending regular 
surveillance endoscopy starting 6 to 8 years after 
first manifestation of the disease in current European 
and United States guidelines[11,12]. Despite the lack 
of randomized controlled trials directly assessing 
the reduction of CAC by surveillance colonoscopy, 
a large number of case series[13-16] and case-control 
studies[17-19] provided evidence of the clinical benefit 
of surveillance colonoscopy for IBD patients. However, 
dysplasia and intraepithelial neoplasia are frequ-
ently missed during routine white-light endoscopic 
examinations[20] and at the same time, random 
biopsies have a low yield for dysplasia detection[20,21]. 
The discovery that dye-based chromoendoscopy 
(e.g., with methylene blue) with targeted mucosal 
biopsies is superior for dysplasia detection in IBD 
patients[20,21] has led to the rapid evolvement of 
advanced endoscopic imaging techniques such as 
digital (i.e., FICE, i-scan, SPIES) or optical [i.e., narrow 
band imaging (NBI), Compound band imaging (CBI)] 
dye-less chromoendoscopy which offer the advantage 
of enhancing mucosal vascular and mucosal surface 
pattern morphology by just pushing a button on 
the handle of the endoscope thereby reducing time 
and costs associated with conventional dye-based 
chromoendoscopy[22,23] (Table 1).
Apart from the detection of early colorectal cancer, 
endoscopic assessment of degree and severity of 
mucosal inflammation is another equally important 
aspect in the management of IBD patients. In this 
regard, mucosal healing has emerged as a key 
treatment goal in IBD in the recent past that predicts 
sustained clinical remission and resection-free survival 
of patients[24]. Hence, the precise assessment of 
intestinal inflammation is of pivotal importance for 
the management of IBD patients and advanced 
endoscopic imaging techniques including dye-less 
chromoendoscopy, endocytoscopy and confocal laser 
endomicroscopy have been shown to allow precise and 
ultrastructural characterization of the inflammation 
within the gut. Finally, by combining endoscopic 
imaging with the visualization of single molecular 
targets crucially involved in disease pathogenesis, in 
vivo endoscopic prediction of therapeutic response 
before the actual commencement of therapy is no 
longer a keen wish for distant future, but close to 
be ready for being integrated into daily practice. In 
this review we describe how novel and advanced 
endoscopic imaging techniques have been utilized for 
the diagnosis and surveillance of CAC and mucosal 
inflammation in IBD patients and follow a semantic 
structure “From the surface to the single cell”. Thus, we 
begin by reviewing imaging techniques that visualize 
the intestinal surface such as chromoendoscopy 
and subsequently discuss endoscopic approaches 
that go deeper within the intestinal layer and are 
capable of visualizing the submucosal architecture 
and single cells such as endocytoscopy and confocal 
endomicroscopy. Finally, we provide an outlook on how 
labelling molecular pathways and targets combined 
with endoscopy can be utilized to make predictions 
about therapeutic responses, thereby tremendously 
expanding the repertoire of modern endoscopy. 
TECHNIQUES BEHIND ADVANCED 
ENDOSCOPIC IMAGING
Magnification endoscopy and chromoendoscopy 
Magnification endoscopy utilizes a movable lens to 
vary the degree of magnification thereby allowing 
to magnify the mucosa of the gastrointestinal tract 
from 6-fold up to 150-fold[25]. In one of the earliest 
studies, magnification endoscopy has been shown 
to be able to differentiate true neoplasms from non-
neoplastic colonic lesions, thereby providing an 
accurate instantaneous prediction of the histology of 
colorectal tumorous lesions[25]. This observation in 
colorectal polyps has now been dramatically extended 
to other neoplastic and non-neoplastic diseases in the 
upper and lower gastrointestinal tract, and especially 
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in combination with chromoendoscopy, magnification 
endoscopy can be utilized for the precise diagnosis of a 
variety of diseases including dysplasia and early cancer 
in the esophagus, stomach and colorectum as well as 
intraepithelial neoplasia and disease extent in UC[26-32].
Chromoendoscopy encompasses dye-based chromo-
endoscopy (DBC) and dye-less chromoendoscopy 
(DLC) and enhances the mucosal architecture and/or 
submucosal microvasculature by the use of various 
dyes (DBC) or endoscopic optical and computer-based 
color programs (DLC). This contrast enhancement 
of the mucosal layer often results in the improved 
detection of lesions that are otherwise subtle or even 
invisible in conventional white-light endoscopy. 
DBC uses different dye agents which are divided 
into absorptive agents (Lugol, methylene blue, 
toluidine blue, and cresyl violet), contrast agents 
(indigo carmine, acetic acid) and reactive staining 
agents (congo red, phenol red), all of which are 
mostly applied via standard spraying or plain biliary 
ERCP catheters[33]. As outlined below, DBC has been 
shown to improve detection of dysplasia in IBD, and 
chromoendoscopy is recommended as the preferred 
modality for surveillance in patients with colonic IBD 
by the British Society of Gastroenterology[34] and 
the European Crohn’s and Colitis organization[35]. 
However, DBC also requires increased effort, skill, 
time, and costs. These confinements associated with 
the use of traditional dye agents have finally led to the 
development of DLC techniques. 
DLC is further subdivided into optical chromo-
endoscopy [Narrow band imaging (NBI), Olympus, 
Japan; Compound band imaging (CBI), Aohua, Shanghai, 
China] and digital chromoendoscopy [i-scan, Pentax, 
Tokyo, Japan; Fujinon Intelligent Color Enhancement 
(FICE), Fujifilm, Tokyo, Japan; Storz Professional 
Image Enhancement Systems (SPIES), Karl Storz, 
Tuttlingen, Germany]. Optical DLC such as NBI utilizes 
optical filters within the light source of the endoscope 
to narrow the bandwidth of spectral transmittance, 
thereby enhancing and facilitating the visualization of 
blood vessels. Digital DLC such as i-scan and FICE uses 
a digital postprocessing algorithm that reconstructs 
the endoscopic image from the video processor in real 
time resulting in an improved contrast of the capillary 
patterns and enhancement of the mucosal surface 
pattern morphology[22,33]. Representative images for the 
enhanced visualization and delineation of the mucosal 
surface pattern by dye-based chromoendoscopy, and 
the mucosal surface and vascular pattern by NBI and 
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Table 1  Techniques and modes of advanced endoscopic imaging with advantages and indications
Endoscopic technique Modes Advantages Disadvantages Indications
White light endoscopy 
(WLE)
Standard definition 
colonoscopy (SD)
Widely spread No sufficient discrimination between 
inflammation and dysplasia
Routine assessment of 
mucosal inflammation
High definition 
colonoscopy
(HD)
Can detect significantly more 
dysplastic lesion in IBD than 
SD[108]
Increased costs compared to SD in combination with DBC: 
cancer surveillance of IBD 
patient[109,110]
Dye based chromo-
endoscopy (DBC)
Indigo-carmine 
(0.8%)[109,110]
Superior for the detection of 
dysplastic lesions 
in IBD[20,21,55,56,109,110] 
Increase in time and effort, dye-
pooling
Method of choice for 
cancer surveillance in 
IBD[12,34,35, 109,110]
Methylene blue 
(1%)[109,110]
Dye less chromo-endoscopy 
(DLC)
   Optical DLC NBI 
CBI
Readily available (push-of-
a-button technologies)[22,31,66] 
improved prediction of disease 
extent and disease activity 
compared to WLE[67-69,71]
NBI: results for dysplasia detection in 
IBD heterogenous 
NBI: not recommended 
as a replacement for DBC 
for cancer surveillance in 
IBD[109,110]
   Digital DLC i-scan 
FICE 
SPIES
i-scan: no data for dysplasia detection 
in IBD yet
Confocal laser 
endomicroscopy (CLE)
pCLE 
iCLE
Real time histologic imaging 
with 1000-fold magnification, 
potentially improved delineation 
of degree and extent of mucosal 
inflammation[82]
Time- and cost-intensive procedure, 
expert skills required[22,31]
No routine indications
Endocytoscopy (EC) Real time histologic imaging with 
up to 1390-fold magnification, 
potentially improved delineation 
of degree and extent of mucosal 
inflammation, can distinguish 
single inflammatory cells[88]
Time- and cost-intensive procedure, 
expert skills required[22,31,111]
No routine indications
CBI: Compound band imaging; DBC: Dye-based chromoendoscopy; DLC: Dye-less chromoendoscopy; FICE: Fuji intelligent color enhancement; HD: High 
definition; IBD: Inflammatory bowel diseases; iCLE: Integrated confocal laser endomicroscop; NBI: Narrow band imaging; SD: Standard definition; SPIES: 
Storz professional image enhancement systems; pCLE: Probe based confocal endomicroscopy.
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Cellvizio, Mauna Kea Technologies, Paris, France); 
and (2) an integrated system in which the CLE probe 
is integrated into the distal end of a high-resolution 
endoscope (“integrated”, iCLE; Pentax, Tokyo, Japan). 
Both system use a blue laser light source that delivers 
an excitation wavelength of 488 nm, and light emission 
from the tissue is detected at wavelengths between 
205 and 585 nm. The iCLE-system collects images 
at a manually adjustable scan rate of 1.6 frames per 
second with a resolution of 1024 × 512 pixels, or at 
0.8 frames per second with a resolution of 1024 × 
1024 pixels. The depth of scanning can be dynamically 
adjusted ranging from 0 to 250 μm and the laser 
power can be manually adjusted between 0 and 1000 
μW. The optical slice thickness is 7 μm, with lateral and 
axial resolution of 0.7 μm and a confocal image field 
of view of 475 μm × 475 μm. Since the laser probe is 
integrated into the endoscope, the accessory channel 
of the endoscope can still be used. 
The pCLE system is based on stand-alone confocal 
probes, and specific probes available for different 
indications throughout the entire gastrointestinal tract 
are available. Probe-based CLE utilizes a fixed laser 
power and a fixed imaging plane depth for image 
acquisition. Lateral resolution ranges between 3.5 μm 
and 1 μm, resulting in a field of view of 600 μm-240 
μm, depending on the confocal probe used. Images 
are acquired at 12 frames/s, leading to real-time 
videos of the intestinal mucosa and single video frames 
either in real time or post processed with an increased 
field of view (4 mm x 2 mm) can be reconstructed 
using a special computer algorithm (Mosaicing, Mauna 
Kea Technologies, Paris, France). Probe based CLE in 
IBD is mostly being performed by using the ColoFlex 
UHD probe which requires a 2.8 mm working channel. 
Hence, these probes can be fitted through the working 
channel of most endoscopes used in clinical practice. 
Depending on the clinical question and the scenario 
in which they are used, both CLE-systems offer unique 
i-scan are shown in Figures 1 and 2, respectively. 
Importantly, both optical and digital DLC are simple 
“push-of-a-button” techniques that are readily 
available during the endoscopic examination. Thus, 
compared to dye-based chromoendoscopy, DLC 
offers the great advantage of dye-enhanced mucosal 
imaging without the efforts in time and costs of 
applying contrast agents during ongoing endoscopy. 
Further, data derived from the in vivo assessment of 
colorectal polyp histology impressively demonstrated 
that DLC can be readily learned even by “non-
expert” endoscopists[36-38]. Hence, endoscopists with 
varying levels of experience can accurately use digital 
chromoendoscopy after a single training session[39,40] 
with comparable diagnostic accuracies between non-
expert and expert endoscopists[41]. 
Confocal laser endomicroscopy
Confocal laser endomicroscopy is a technique allowing 
to obtain images at the (sub)cellular level[42], and since 
its introduction in 2003 confocal laser endomicroscopy 
(CLE) has rapidly emerged as a powerful technique 
that enables precise histologic real time in vivo 
imaging of various diseases[43-47]. Technically, CLE is 
based on the emission of a low power blue laser into 
the tissue after topical (acriflavine hydrochloride, 
cresyl violet) or systemic (fluorescein sodium) 
administration of contrast agents. The emitted light 
is then reflected from the tissue and refocused on 
the detection system by the same lens, leading to 
microscopic imaging at 1000-fold magnification in 
real time. As shown in healthy mucosa in Figure 3, 
CLE allows a clear visualization of the colonic crypt 
architecture, single cells within the lamina propria and 
the microvasculature within the colon[45]. Currently, 
two FDA-approved and CE-certified CLE devices are 
available and used in clinical routine[48]: (1) a probe 
based CLE system that can be inserted into the 
accessory channel of any standard endoscope (pCLE, 
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Figure 1  Dye-based chromoendoscopy and optical chromoendoscopy in the gastrointestinal tract.  Left picture: Optical dye-less chromoendoscopy with 
narrow band imaging (NBI) is based on the utilization of optical filters within the light source of the endoscope to narrow the bandwidth of spectral transmittance, 
thereby enhancing and facilitating the visualization of blood vessels. As exemplified on a fundic gland polyp in the stomach, NBI allows a clear delineation of the 
mucosal surface pit pattern architecture. Right picture: Dye-based chromoendoscopy with indigo carmine. Indigo carmine is a blue contrast agent that is used primarily 
in the colon for enhancing the detection or differentiation of colorectal neoplasms. As shown for a small colon polyp here, application of indigo carmine via a spraying 
catheter enhances the contrast and allows to visualize the pit pattern and to delineate mucosal irregularities. 
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advantages and specifications. Advantages of the 
integrated system are its higher resolution and the 
possibility to alter the laser power and imaging plane 
depth, whereas the pCLE system allows ad hoc usage 
in existing endoscopes and enables real time video 
recording. 
Endocytoscopy 
Endocytoscopy (EC) allows in vivo microscopic imaging 
of the GI tract with an magnification ranging from 
340-fold up to 1390-fold[49-51] and is based on the 
principle of contact light microscopy. EC utilizes a 
fixed-focus, high-power objective lens that projects 
highly magnified images from a sampling site onto a 
charge-coupled device[49-51]. The depth of field ranges 
from 0 to 50 μm and therefore only allows visualization 
of the very superficial mucosal layer. EC requires 
thorough mucolysis which can be performed with 
N-acetyl-cysteine. Further, prestaining of the mucosa 
with an absorptive agent such as methylene blue, 
toluidine blue, or cresyl violet is required. Optimal 
endocytoscopic mucosal imaging can be obtained with 
1% methylene blue in the oesophagus and with 0.25% 
toluidine blue in the stomach and colon after 60 s of 
exposure to the dye[52].
In fact, a combination of different dye agents is 
often used to generate optimal tissue contrast and 
imaging modalities[53]. With the use of absorptive 
agents via spraying catheters, repeated staining of 
the mucosa may be needed when the clinical scenario 
requires extended visualization[50]. Endocytoscopy 
images are displayed on a monitor at 30 frames per 
second, which corresponds to the frame rate during 
routine high-resolution video endoscopy.
Currently, two systems of endocytoscopes are 
available[50]. Similar to the CLE devices, endocytoscopy 
devices can be integrated into the distal tip of a 
standard endoscope (iEC) or utilized as a probe that is 
advanced through the working channel of a standard 
endoscope (pEC). Endoscope-based instruments use 
two different lenses and integrate the EC component 
within upper (103 cm in length) and lower (133 
cm in length) endoscopes and provide a 580x-fold 
image magnification on a 19-inch monitor, in addition 
to having conventional optical magnification and 
narrow band imaging capabilities. Recently, another 
endocytoscopy system (GIF-Y0002) was introduced 
consisting of only one lens that allows continuous 
increase of zooming power from the conventional 
endoscopy level up to 380-fold (tissue field of view, 
700 mm x 600 mm) using a hand lever. Using digital 
magnification (x 1.6), the magnifying power can 
be increased to 600-fold, providing a tissue field of 
view measuring 440 mm x 380 mm[51,54]. For the 
first time, this new endoscope-generation enables 
continues magnification from standard overview to 
endocytoscopy therefore representing an “all-in-one” 
scope.
Currently, two different probe-based EC devices 
exist, providing either 450-fold (XEC 300F) or 
1390-fold (XEC 120 U) magnification images on a 
19-inch monitor[50,51]. The probes are 380 cm in length 
and 3.2 mm in diameter thus requiring an accessory 
channel of 3.7 mm. The horizontal observation field 
is given with 300 μm x 300 μm (0.09 mm2) for the 
450-fold magnification probe and with 120 μm x 120 
μm for the 1390-fold magnification probe. Similar to 
what is already discussed with different CLE devices, 
one of the major advantages of the probe-based EC 
system lies in its ad hoc usability in already existing 
endoscopes whereas the integrated EC devices allow 
to simultaneously take biopsies and thus to directly 
compare EC imaging with histopathological results.
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Figure 2  Digital dye-less chromoendocopy with i-scan in the lower 
gastrointestinal tract. i-scan uses a digital postprocessing algorithm that 
reconstructs the endoscopic image from the video processor in real time 
resulting in improved contrast of the capillary patterns and enhancement of the 
mucosal surface pattern morphology as exemplified on a adenomatous polyp 
in the colon. As a result of an accumulation of lipid-filled macrophages within 
the lamina propria, the mucosa adjacent to the polyp exhibits a chicken skin 
mucosa on digital chromoendoscopy.
20 μm
Figure 3  Confocal laser endomicroscopy in the lower gastrointestinal 
tract. Confocal laser endomicroscopy (CLE) is based on the emission of a 
low power blue laser into the tissue after topical or systemic administration 
of contrast agents. The emitted light is then reflected from the tissue and 
refocused on the detection system by the same lens, leading to microscopic 
imaging at 1000-fold magnification in real time. As shown in healthy colonic 
mucosa in this picture, CLE allows a clear visualization of the colonic crypt 
architecture, single cells within the lamina propria and the microvasculature 
within the colon.
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ROLE AND APPLICTIONS OF ADVANCED 
ENDOSCOPIC IMAGING IN IBD
surface level: Dye-based and dye-less 
chromoendoscopy 
In one of the earliest prospective randomized trials on 
the relevance of dye-based chromoendoscopy (DBC) 
for the assessment of mucosal inflammation and 
dysplasia in UC, Kiesslich et al[21] directly compared 
DBC and conventional colonoscopy in a large cohort 
of UC patients. Importantly, DBC with methylene 
blue not only permitted a more accurate diagnosis of 
the extent and severity of the inflammatory activity 
in UC compared with conventional colonoscopy, but 
also significantly improved the early detection of 
intraepithelial neoplasia and CAC. Another “back-
to-back” study evaluated pancolonic indigo carmine 
staining (0.1%) for the detection of UC-associated 
dysplasia[20]. As shown in this study, DBC with indigo 
carmine led to a higher dysplasia detection rate 
while at the same time reducing the total amount of 
biopsies[20]. Consistent with these results, another 
prospective trial also included patients with Crohn’s 
colitis (CC), and similarly, in both UC and CC, targeted 
biopsies with dye spray (methylene blue) detected 
significantly more dysplasia than random biopsies 
that were taken without the utilization of dye[55]. As 
shown in a recent meta-analysis of six randomized 
controlled trials, dye-based chromoendoscopy has 
a medium to high sensitivity and a high diagnostic 
accuracy for dysplastic lesions in UC[56] and the typical 
features of UC associated dysplasia on DBC (and 
conventional endoscopy) have been summarized by 
Matsumoto et al[57] from the Hyogo College of Medicine 
in Japan. Since white-light endoscopy exhibits only low 
interobserver agreement in differentiating dysplastic 
from non-dysplastic lesions during colitis surveillance, 
current guidelines recommend chromoendoscopy with 
targeted biopsies as the surveillance procedure of 
choice for appropriately trained endoscopists, whereas 
white-light endoscopy with random biopsies (quadrant 
biopsies every 10 cm) remains a reasonable alternative 
for cancer surveillance in IBD patients[11,12,58].
Since DBC is also associated with a potential 
increase in examination time, costs and overall 
effort, a recent study evaluated whether DBC is cost-
effective for colorectal cancer surveillance in UC 
patients. Interestingly, DBC with targeted biopsies is 
not only more effective but also less costly compared 
to conventional white-light endoscopy with random 
biopsies[59]. In its totality, this profound evidence on 
the superiority of DBC for the detection of colitis-
associated neoplasia, together with the knowledge of 
a cumulative CRC risk in UC patients of 18% after 30 
years of disease[7], have led to the recommendation to 
perform chromoendoscopy with targeted biopsies as 
the surveillance procedure of choice in IBD patients in 
US and European guidelines[11,12,34,35].
The first case in which optical DLC was used to help 
in identifying colitis associated neoplasia was a 63 
year old man with longstanding ulcerative colitis and 
a previous history of dysplasia associated lesions or 
masses (DALM). In this patient it was shown for the 
first time that visualization of the pit pattern and the 
vascular pattern intensity by NBI might help in DALM 
detection and to distinguish dysplastic from non-
dysplastic mucosa in ulcerative colitis[60]. Especially 
the capillary vasculature in dysplastic lesions exhibited 
a higher vascular pattern and appeared darker on 
NBI compared to adjacent normal mucosa[60]. Since 
then, various trials have studied the potential of NBI 
to assess mucosal inflammation and colitis associated 
preneoplastic and neoplastic changes, with so far 
mixed results. In one of the earliest reports, the 
Amsterdam group compared the accuracy of NBI with 
standard colonoscopy for the detection of neoplasia in 
patients with longstanding ulcerative colitis[61]. Although 
more suspicious lesions were found during DLC with 
NBI, the sensitivity of NBI for neoplasia detection 
was similar to conventional white-light endoscopy[61]. 
Soon thereafter, the same group assessed the value 
of NBI for surveillance in UC in two other studies[62,63]. 
In these studies, pit pattern analysis of neoplastic 
lesions exhibited only a moderate accuracy for the 
prediction of histology[62] and also NBI did not improve 
the detection of UC associated neoplasia compared 
to high-definition endoscopy[63]. Nevertheless, NBI 
has been shown to be equally effective in detecting 
UC associated intraepithelial neoplasia compared to 
conventional dye-based endoscopy and exhibited a 
reduced false-positive biopsy rate and a similar true-
positive rate[64]. However, the high miss rate with NBI, 
as pointed out by the authors themselves, makes 
NBI not advisable as the standard technique to detect 
dysplasia in patients with long-standing IBD[64] and 
clearly, higher powered studies are needed to address 
this question[65,66]. 
The role of dye-less chromoendoscopy to assess 
mucosal inflammation associated with IBD has also 
been studied. In one of the earliest reports, Kudo et 
al[67] analyzed the mucosal vascular pattern (MVP) in 
patients with asymptomatic or mildly active UC using 
NBI and HD white-light endoscopy. The authors found 
that areas with obscure MVP on NBI exhibit increased 
numbers of acute inflammatory cell infiltrates, goblet 
cell depletion and basal plasmacytosis and that 
evaluation of the MVP with NBI yielded a more precise 
determination of acute microscopic inflammation in 
patients with quiescent UC[67]. The typical appearance 
of active UC and inactive, quiescent disease on 
NBI have been summarized by the same group of 
authors[68]. In addition to that, another pilot study 
on 14 IBD patients was able to demonstrate that 
areas that appear normal on WLE, but positive on 
NBI (as defined by a stronger capillary vascular 
pattern), exhibit an increased leukocyte infiltrate 
11265 October 28, 2015|Volume 21|Issue 40|WJG|www.wjgnet.com
Rath T et al . Novel endoscopic approaches in IBD
and a significantly increased microvessel density 
on immunohistology, thus providing first evidence 
that NBI might allow in vivo imaging of intestinal 
neoangiogenesis in IBD patients[69]. 
Data on the relevance of digital DLC for the 
assessment of mucosal inflammation in IBD patients 
are limited. To date, only one study evaluated FICE 
in IBD patients and showed that FICE is not helpful 
to improve the detection or delineation of ulcers 
and erosions in CD[70]. Just recently, a study on 78 
IBD patients that were randomized to receive either 
HD white-light endoscopy or HD endoscopy with 
i-scan, was able to demonstrate that i-scan allows a 
considerably improved prediction of disease extent and 
disease activity compared to white-light endoscopy 
(i-scan: 92% and 90% vs WLE: 49% and 54%)[71]. 
Of note, examination time was not different between 
WLE and i-scan, consistent with the idea that dye-less 
chromoendoscopy is a push-of-a-button technology 
that can be readily incorporated into the existing 
examination[71]. Although no studies have directly 
assessed the relevance of digital chromoendoscopy for 
the detection of colitis-associated neoplasia and cancer, 
it has been shown that HD endoscopy with i-scan can 
detect significantly more neoplastic lesions and more 
flat adenomas than standard resolution endoscopy[72] 
and is as precise as dye-based chromoendoscopy 
for the characterization of small colorectal lesions[73]. 
Based on these results, data on the assessment of 
colitis associated dysplasia by digital DLC are eagerly 
awaited. 
cellular level: Confocal laser endomicroscopy 
The technical application of confocal endomicroscopy 
and the interpretation of images for the utilization in 
IBD patients can be readily learned. In this regard, it 
has been shown that after an initial three examinations, 
performance of CLE significantly improves with a 
decreased confocal imaging time, successful CLE 
diagnosis and decline in overall procedural time[74]. In 
one of the first in vivo studies for dysplasia detection, 
it was shown that using chromoendoscopy (methylene 
blue) together with endomicroscopy can detect 
significantly more neoplasia compared to conventional 
white-light endoscopy while at the same time requiring 
50% fewer biopsies[75]. Soon thereafter, CLE was 
proven to be accurate also for the differentiation 
between DALM and adenoma-like mass (ALM), thereby 
facilitating the clinical decision whether patients should 
receive endoluminal endoscopic resection or be rather 
referred for proctocolectomy[76]. Importantly, these 
studies utilized the integrated CLE system (iCLE) and 
subsequently, another pilot study utilizing probe-based 
CLE demonstrated that pCLE for dysplasia surveillance 
in UC is also feasible with reasonable diagnostic 
accuracy[77] and the typical appearance of DALM on CLE 
against inflammatory changes has been characterized 
as dark cells with crypt density attenuation, a ridged-
lined irregular epithelial layer with loss of crypts and 
dilated and distorted vessels with elevated leakage 
and irregular vascular architecture[42,78]. A recent meta-
analysis on the relevance of CLE for dysplasia detection 
in either patients with sporadic polyps or IBD patients 
calculated that CLE can distinguish neoplasms from 
non-neoplastic tissue in IBD patients with a sensitivity 
of 83% and specificity of 90%, thereby confirming that 
CLE can indeed differentiate between neoplastic and 
non-neoplastic tissue[79]. 
CLE also has been proven to be accurate and 
efficient for the real-time in vivo assessment of 
mucosal inflammation associated with IBD. One of 
the earliest pilot studies assessed the morphologic 
differences on CLE between active and inactive UC 
and it was shown that colonic crypts in non-active 
UC are small, round and slightly irregularly arranged 
with small and round crypt lumina, whereas colonic 
crypts in active UC appear large, variously shaped, 
irregularly arranged with numerous inflammatory 
cells and capillaries in the lamina propria[80]. Soon 
thereafter, Li et al[81] utilized a 4-grade classification 
of crypt architecture combined with an analysis of 
microvascular alterations and fluorescein leakage 
to establish a CLE based classification system for 
assessment of inflammatory activity in UC patients. 
All three parameters (crypt architecture, fluorescein 
leakage, microvasculature) did correlate well with 
histology, and more than 50% of the patients with 
normal appearing mucosa on conventional white-
light endoscopy exhibited acute inflammation on 
histology whereas no patient with normal mucosa 
on CLE showed acute inflammation on histology[81]. 
Results from our own group indicate that CLE can also 
reliably assess Crohn’s disease activity: a significantly 
higher proportion of patients with active CD had 
increased colonic crypt tortuosity, enlarged crypt 
lumen, microerosions, augmented vascularization, 
and increased cellular infiltrates within the lamina 
propria. In quiescent CD, a significant increase in crypt 
and goblet cell number was detected compared with 
controls[82] and based on these findings, we proposed 
the Crohn’s Disease Endomicroscopic Activity Score 
(CDEAS) for the assessment of Crohn’s disease activity 
in vivo. The CDEAS does not only allow to differentiate 
between quiescent CD and controls but also between 
quiescent and active disease and shows strong 
correlation to serum levels of the C-reactive protein[82]. 
Hence, the CLE and the CDEAS are accurate tools 
for the accurate prediction of disease severity in CD 
patients[82]. 
Epithelial gaps, as originally described on CLE by 
Kiesslich et al[83] result from shedding of epithelial cells 
and are of particular relevance for the endomicroscopic 
evaluation of inflammatory activity in IBD patients. As 
shown by Liu et al[84], patients with CD exhibit a higher 
gap density than controls and increased epithelial gap 
density in the small intestine is a predictor for future 
hospitalization or surgery in IBD patients[85]. Further, 
increased cell shedding with fluorescein leakage is 
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associated with subsequent relapse within 12 mo after 
confocal examination in IBD patients in remission and 
a CLE based grading system assessing cell shedding 
and local barrier dysfunction can predict disease flares 
with high specificity[86]. 
Taken together, these results demonstrate that 
CLE can be used to reliably assess the macro- and 
microscopic inflammatory activity in IBD patients 
and to obtain tissue histology in real-time. Since the 
precise determination of mucosal inflammation is of 
paramount importance to achieve mucosal healing as 
a key prognostic parameter and important treatment 
goal in IBD patients[24], it can be expected that CLE 
will experience a wider-spread utilization not only 
to facilitate and optimize the management and 
surveillance of IBD patients but also to prospectively 
identify patients that are under risk of experiencing a 
disease flare. 
cellular level: Endocytoscopy 
Compared with CLE, less data on the role of EC 
for the evaluation of mucosal inflammation in IBD 
patients are available. In an initial report utilizing 
an EC system with 450-fold magnification, a newly 
introduced endocytoscopy score assessing the shape 
and distance between crypts as well as the visibility of 
superficial microvessels showed a strong correlation 
with Matts’ histopathological grading[87] and a high 
reproducibility between different investigators[87]. 
Recently, our own group tackled the issue whether 
EC can not only determine inflammatory activity 
in IBD, but also discriminate single inflammatory 
cells. For this purpose, we utilized a probe-based EC 
system with 1390-fold magnification on 19 patients 
with CD and 21 patients with UC[88]. In this report, 
we were able to demonstrate that EC is able to 
reliably distinguish single inflammatory cells, namely 
neutrophilic, basophilic and eosinophilic granulocytes, 
and lymphocytes[88]. Further, concordance between 
endocytoscopy and histopathologic grading of disease 
activity was 100% and EC exhibited a substantial 
interobserver and almost perfect intraobserver 
agreement[88]. The detection of colitis- associated 
neoplasia or cancer with EC has not been studied to 
date. However, first evidence suggests that EC can 
identify dysplasia in aberrant crypt foci as the earliest 
precursor lesions of colorectal cancer in the dysplasia-
carcinoma sequence[89]. In colonic polyps, EC is 
capable to even detect and distinguish focal high-grade 
intraepithelial neoplasia[90]. Based on these results, 
EC is a promising imaging technique that might allow 
microscopic real-time identification of colitis-associated 
neoplasia. 
subcellular level: Molecular targeting and molecular 
imaging 
Molecular imaging is based on the utilization of 
fluorophores with specificity towards a defined 
molecular target, thereby allowing in vivo visualization 
on the sub-cellular molecular level. Molecular imaging 
is a rapidly evolving field and with the ongoing 
identification of crucial molecules involved in the 
immunopathogenesis of intestinal diseases in basic 
research, a steadily growing arsenal of targets that 
can be visualized with molecular imaging becomes 
available. The ideal probes utilized for molecular 
imaging in the gastrointestinal tract should exhibit the 
following characteristics: high diversity, high affinity 
binding, rapid binding kinetics within minutes, adequate 
tissue penetration, low immunogenicity, ability for 
large scale synthesis and florescent labelling[91]. Agents 
that have been utilized for molecular imaging include 
the following substance classes: antibodies, lectines, 
affinity peptides, activatable probes, nanoparticles 
and physiological substances[92-94]. So far, molecular 
imaging has been successfully evaluated in mucosal 
inflammation and cancer development in both, mice 
and humans. Just recently, Mitsunaga et al[95] utilized 
a topically applied enzymatically activatable probe 
(gGlu-HMRG) which fluoresces in the presence of 
γ-glutamyltranspeptidase (GGT), an enzyme associated 
with cancer, to study colitis-associated cancer detection 
in a murine model. Using fluorescence colonoscopy in 
mice, gGlu-HMRG fluorescent lesions were detected 
5 min after topical administration, even in small 
lesions, and fluorescence persisted for at least 30 min. 
Importantly, at autopsy such lesions corresponded to 
tumour-containing lesions in all cases analyzed and 
microscopic inflammatory infiltration exhibited a much 
lower signal than cancer[95]. Consistent with these 
observations, others studies successfully detected 
intestinal dysplasia and polyps in murine and xenograft 
models via the utilization of protease-sensing probes 
such as a cathepsin reporter probes[96,97], MMP-
activatable probes[98], substrates of the γ-glutamylt
ranspeptidase[95,99], or certain peptides[100,101]. Apart 
from that, other studies have chosen molecular 
targets that are known to be upregulated in colorectal 
cancer and are already established therapeutic 
targets such as epidermal growth factor receptor 
(EGFR) or vascular endothelial growth factor receptor 
(VEGFR) as fluorescent probes for the detection and 
precise discrimination of colorectal cancer[102,103]. 
When targeting VEGFR with fluorescently labeled 
antibodies, CLE visualized the distribution of VEGF 
in the malignantly transformed tissue in rodent and 
xenografted models of colon cancer, as well as in 
human specimens, and thus allowed identification of 
cancer cells on subcellular level[102]. For EGFR it was 
shown that EGFR expression levels of different tumors 
cell lines in xenograft models could be discriminated in 
vivo in mice with CLE and that topical administration, 
i.e., the incubation of human colon cancer specimens 
with the antibody, allowed discerning neoplastic tissue 
from healthy mucosa[103]. Similar observations were 
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made in a murine model of gastric cancer[104]. In this 
study, anti-EGFR antibodies as molecular probes not 
only successfully identified tumor xenografts but also 
allowed to visualize the subcellular distribution of 
EGFR[104]. Based on these results, a first human study 
was conducted just recently in which the fluorescently-
labeled anti-EGFR antibody cetuximab was topically 
applied in CRC patients[105]. Upon visualization with 
CLE, an EGFR-specific fluorescence signal was present 
in 18 out of 19 patients with CRC and 12 out of 
18 patients with intestinal adenomas while normal 
mucosa exhibited no or only weak fluorescence[105].
These findings were directly translated into 
clinical applications and first pre-clinical trials have 
impressively demonstrated that the visualization 
of molecular targeted can be utilized for a risk-
stratification of individual patients which allows to 
predict therapeutic response a priori to the initiation 
of treatment. One of the first studies that provided 
proof-of-concept utilized nude mice transplanted with 
colon cancer xenografts with either high or low EGFR 
expression[106]. CLE was performed 48 h after injection 
of a test dose of fluorescently labelled cetuximab and 
subsequently received cetuximab as a cancer treating 
agent. Importantly, the CLE-assessed fluorescence 
intensity before initiation of therapy predicted the 
response to subsequent cetuximab treatment as 
shown in a significantly slower tumor progression, 
better physical condition, and longer overall survival 
in mice that exhibited tumors with high anti-EGFR 
fluorescence at the initial evaluation[106]. 
Just recently it has been shown that molecular 
imaging with fluorescently labeled antibodies and 
CLE can successfully be used to stratify IBD patients 
prior to the initiation of treatment into responders and 
non-responders, thereby allowing a prediction on the 
therapeutic success. 
In this seminal first phase 1 clinical trial, a fluo-
rescently labeled anti-TNF antibody (FITC-adalimumab) 
was topically applied to the inflamed mucosa of IBD 
patients during endoscopy via a spraying catheter, and 
subsequently, the amount of intestinal mTNF+ cells 
was quantified via CLE[107]. Importantly, patients with 
high numbers of mTNF+ cells showed significantly 
higher short-term response rates (92%) at week 12 
upon subsequent anti-TNF therapy as compared to 
patients with low amounts of mTNF(+) cells (15%), 
despite comparable severity of mucosal inflammation 
in both patient groups. This clinical response in 
patients with high amounts of intestinal mTNF+ cells 
was sustained over a follow-up period of 1 year and 
was associated with mucosal healing observed at 
follow-up endoscopy[107]. Hence, these data were the 
first to indicate that molecular imaging with fluorescent 
antibodies and CLE has the potential to predict 
therapeutic responses to biological treatment in CD 
and might be used for personalized medicine in IBD 
and potentially other autoimmune or inflammatory 
disorders. The establishment of this approach and its 
widespread integration into daily endoscopic routine 
and patient care would have a tremendous impact 
since it will not only allow to avoid unnecessary risk 
exposure associated with biological therapies but 
would also lead to a considerable economization of the 
treatment regimens.
In summary, as contoured by the studies described 
above, molecular imaging is a rapidly emerging field 
in advanced endoscopic imaging and will likely have 
paradigm-shifting consequences for daily practice in 
the foreseeable future. With this approach, endoscopy 
is in the center of attention and allows the endoscopist, 
apart from diagnosis and treatment, to acquire a third 
key competence in medicine: prediction on individual 
patient level. 
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